Lumos Diagnostics Holdings Ltd (LDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lumos Diagnostics Holdings Ltd (LDX) has a cash flow conversion efficiency ratio of 0.149x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$778.03K ≈ $550.51K USD) by net assets (AU$5.24 Million ≈ $3.70 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Lumos Diagnostics Holdings Ltd for the company's overall valuation and market capitalisation.
Lumos Diagnostics Holdings Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Lumos Diagnostics Holdings Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Lumos Diagnostics Holdings Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lumos Diagnostics Holdings Ltd ranked by their cash flow conversion efficiency. See Lumos Diagnostics Holdings Ltd (LDX) cash flow to debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kilitch Drugs (India) Limited
NSE:KILITCH
|
-0.025x |
|
Satia Industries Limited
NSE:SATIA
|
0.082x |
|
Sentelic Corp
TWO:4945
|
-0.084x |
|
Novogenia AG
XETRA:7V0
|
N/A |
|
Thai Wah Public Company Limited
BK:TWPC
|
-0.001x |
|
Hai Kwang Enterprise Corp
TW:2038
|
0.183x |
|
Tripar Multivision Plus
JK:RAAM
|
0.042x |
|
Lokesh Machines Limited
NSE:LOKESHMACH
|
-0.077x |
Annual Cash Flow Conversion Efficiency for Lumos Diagnostics Holdings Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Lumos Diagnostics Holdings Ltd from 2017 to 2024. View Lumos Diagnostics Holdings Ltd share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | AU$6.16 Million ≈ $4.36 Million |
AU$-9.33 Million ≈ $-6.60 Million |
-1.516x | -1239.24% |
| 2023-12-31 | AU$7.11 Million ≈ $5.03 Million |
AU$946.00K ≈ $669.36K |
0.133x | +113.11% |
| 2022-12-31 | AU$9.50 Million ≈ $6.72 Million |
AU$-9.64 Million ≈ $-6.82 Million |
-1.015x | -0.62% |
| 2021-12-31 | AU$17.89 Million ≈ $12.65 Million |
AU$-18.04 Million ≈ $-12.76 Million |
-1.008x | -439.75% |
| 2020-12-31 | AU$58.28 Million ≈ $41.24 Million |
AU$-10.89 Million ≈ $-7.70 Million |
-0.187x | -10.16% |
| 2019-12-31 | AU$22.16 Million ≈ $15.68 Million |
AU$-3.76 Million ≈ $-2.66 Million |
-0.170x | +34.83% |
| 2018-12-31 | AU$11.66 Million ≈ $8.25 Million |
AU$-3.03 Million ≈ $-2.15 Million |
-0.260x | -168.72% |
| 2017-12-31 | AU$2.98 Million ≈ $2.11 Million |
AU$-288.67K ≈ $-204.25K |
-0.097x | -- |
About Lumos Diagnostics Holdings Ltd
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, … Read more